Efficacy of ciprofloxacin and clarithromycin in acute bacterial exacerbations of complicated chronic bronchitis: Interim analysis

Clinical Therapeutics

Volumn 19, Issue 5, 1997, Pages 989-1001

  Anzueto, Antonio ^a   Niederman, Michael S ^b   Haverstock, Daniel C ^c   Tillotson, Glenn S ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

^c BAYER CORPORATION   (United States)

Author keywords

Acute exacerbations of chronic bronchitis; Ciprofloxacin; Clarithromycin

Indexed keywords

CIPROFLOXACIN; CLARITHROMYCIN;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CHRONIC BRONCHITIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HAEMOPHILUS INFLUENZAE; HUMAN; MAJOR CLINICAL STUDY; MORAXELLA CATARRHALIS; MULTICENTER STUDY; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0030701971     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80051-3     Document Type: Article

References (33)

1. Petty TL. A new national strategy for COPD. J Respir Dis. 1997; 18:365-369.
2. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152 (Suppl):S77-S120.
3. National Heart, Lung, and Blood Institute. Morbidity and Mortality: 1996 Chartbook on Cardiovascular, Lung, and Blood Diseases. Bethesda, Maryland: National Institutes of Health; 1996:5-9,49-53.
4. Higgins MW, Thom T. Incidence, prevalence, and mortality: Intra- and intercountry differences. In: Hensley MJ, Saunders NA, eds. Clinical Epidemiology of Chronic Obstructive Pulmonary Disease. New York: Marcel Dekker; 1990:23-43.
5. Frank SH, Jaen CR. Office evaluation and treatment of the dependent smoker. Prim Care. 1993;20:251-268.
6. Chodosh S. Bronchitis and asthma. In: Gorbach SL, Bartlett JG, and Blacklow NR, eds. Infectious Diseases. Philadelphia: WB Saunders; 1992:476-485.
7. Leeper KV, Jones AM, Tillotson G. The changing bacterial etiology of chronic obstructive pulmonary disease (COPD). Abstract presented at Chest 1997, the 63rd Annual International Scientific Assembly of the American College of Chest Physicians, October 26-30, 1997, New Orleans, Louisiana.
8. Eller J, Ede A, Rossdeutscher R, et al. Sputum bacteriology of acute infectious exacerbations: Chronic obstructive pulmonary disease vs bronchiectasis. Eur Respir J. 1996;23(Suppl 9):107S. Abstract.
9. Doern GV, Brueggemann AB, Holley HP Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996;40:1208-1213.
10. Doern GV, Brueggemann AB, Pierce G, et al. Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996;40:2884-2886.
11. Doern GV, Brueggemann AB, Pierce G, et al. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase positive strains resistant to amoxicillin-clavulanate: Results of a national multicenter study. Antimicrob Agents Chemother. 1997;41: 292-297.
12. Felmingham D, Gruneberg RN, the Alexander Project Group. A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: The Alexander Project. J Antimicrob Chemother. 1996:38(Suppl A): 1-57.
13. Gruneberg RN, Felmingham D, the Alexander Project Group. Results of the Alexander Project: A continuing multicenter study of the antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens. Diagn Microhiol Infect Dis. 1996;25:169-181.
14. Saint S. Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA. 1995;273:957-960.
15. Balter MS, Hyland RH, Low D, et al. Recommendations on the management of chronic bronchitis: A practical guide for Canadian physicians. Can Med Assoc J. 1994;10(Suppl):5-23.
16. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest. 1995;108(Suppl):43S-52S.
17. Chodosh S, McCarty J, Farkas S, et al. Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for the treatment of acute bacterial exacerbations of chronic bronchitis. Abstract presented at the 33rd annual meeting of the Infectious Diseases Society of America. September 16-18, 1995, San Francisco, California.
18. Chodosh S, Schreurs A, Siami G, et al. The efficacy of oral ciprofloxacin vs clarithromycin for the treatment of acute bacterial exacerbations of chronic bronchitis. Abstract presented at the 34th annual meeting of the Infectious Diseases Society of America, September 18-20, 1996, New Orleans, Louisiana.
19. Wise R, Andrews JM, Edwards LJ. In vitro activity of Bay 09867, a new quinolone derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother. 1983;23:559-564.
20. Chin N, Neu HC. Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother. 1984; 25:319-326.
21. Ritrovato CA, Deeter RG. Respiratory tract penetration of quinolone antimicrobials: A case in study. Pharmacotherapy. 1991;11:38-49.
22. Anthonisen NR, Manfeda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.
23. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests. Document M2-A4. 4th ed. Villanova, Pennsylvania: NCCLS; 1990.
24. Basran GS, Joseph J, Abbas AM, et al. Treatment of acute exacerbations of chronic obstructive airways disease - a comparison of amoxycillin and ciprofloxacin. J Antimicrob Chemother. 1990;26 (Suppl F): 19-24.
25. Gleadhill IC, Ferguson WP, Lowry RC. Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxycillin. J Antimicrob Chemother. 1986;18(Suppl D):133-138.
26. Chmel H, Emmanuel G, Lie T, et al. A prospective, double-blind, randomized study comparing the efficacy and safety of low-dose ciprofloxacin with ampicillin in the treatment of bronchitis. Diagn Microbiol Lab Med. 1990; 13:149-151.
27. Hoogkamp-Korstanje JAA, Klein SJ. Ciprofloxacin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1986; 18:407-413.
28. Davies BI, Maesen FPV, Baur C. Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis. Eur J Clin Microbiol. 1986;5:226-231.
29. Bachand RTJ. Comparative study of clarithromycin and ampicillin in the treatment of patients with acute exacerbations of chronic bronchitis. J Antimicrob Chemother. 1991;27(Suppl A):S91-S100.
30. Quay DRP, Craft JC. Comparative safety and efficacy of clarithromycin and ampicillin in the treatment of out-patients with acute bacterial exacerbations of chronic bronchitis. J Intern Med. 1992;231: 295-301.
31. Aidons PM. A comparison of clarithromycin with ampicillin in the treatment of outpatients with acute bacterial exacerbation of chronic bronchitis. J Antimicrob Chemother. 1991;27(Suppl A): 101-108.
32. Chodosh S, Tuck J, Stottmeier KD, Pizzuto D. Comparison of ciprofloxacin with ampicillin in acute infectious exacerbations of chronic bronchitis. Am J Med. 1989;87(Suppl 5A):107S-112S.
33. Wollschlager CM, Raoof S, Khan FA, et al. Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections. Am J Med. 1987;82(Suppl 4A): 164-168.